Injectable Steroids

Boldenone Undecylenate 250 mg Primus Ray Laboratories

Primus Ray Laboratories

60,00

In Stock (100 available)

Boldenone Undecylenate 250 mg Primus Ray Laboratories (250 mg) — Athletes seeking the perfect balance between mass accrual and aesthetic quality consistently turn to Boldenone. Its ability to boo…

100 in stock

This product is for laboratory research use only. Not for human consumption.

5+ −10%
10+ −15% Best price
Third-Party Lab Report HPLC verified
CoA available on request — email support@vitalquests.org with the batch code from your vial.
HPLC TestedBatch report available
No Labels on BoxPlain brown parcel
Pay the CourierCash on delivery only
Ships TodayOrder before 14:00
€85+ = free shipping
EU warehouse — no customs, no delays
Tracked via DHL / DPD / InPost

Description

Boldenone (Equipoise), Primus Ray Laboratories, 250 mg. EPO-stimulating anabolic — increased red blood cell count drives oxygen delivery and vascularity. Low estrogenic activity (~50% of testosterone aromatisation rate). Monitor hematocrit during longer cycles.

Key Benefits

  • Slow, steady lean-mass accrual — the patient lifter’s compound
  • Increased RBC production and vascularity
  • Mild oestrogenic conversion — AI usually sufficient at low dose
  • Appetite enhancement supports off-season caloric surpluses
  • Minimal androgenic sides at typical performance doses
  • Each unit dosed at 250 mg — see Recommended Dosage below for protocol-specific intake

Recommended Dosage

Research dosing: 400–600 mg/week. Often front-loaded at 800 mg week 1 to speed up saturation (long ester takes 5+ weeks otherwise). Cycles 14–20 weeks. Above 800 mg/week lipid and BP effects grow without proportional gain.

How It Works

Dihydrotestosterone with a 1,2-double bond — structurally close to methandienone but without the 17α-methyl group, so no oral bioavailability and no hepatotoxicity. Converts weakly to estradiol (~half the rate of testosterone). Also metabolises to a hydroxylated form that can act as a mild AI itself.

Pharmacokinetics

Undecylenate ester. Plasma half-life approximately 14 days. Steady-state at 4–5 weeks without front-load; 2 weeks with. Weekly or bi-weekly pinning fine. Long clearance — PCT at week 3 post-last-injection.

Cycle & Stacking Guide

Long lean-gain cycles 16–20 weeks. Classic pairing: test E 400 mg/week + EQ 600 mg/week + (optional) winstrol or anavar for final 6 weeks. Not a first-cycle compound — long duration demands disciplined bloodwork and diet.

Manufacturer Notes

Primus Ray Laboratories focuses on injectable AAS at standard concentrations. Each SKU ships with a batch-date coded label.

Storage & Handling

Store upright at 15–25 °C in the original box, protected from light and moisture. Oil-based injectables are shelf-stable for the duration printed on the vial when kept at controlled room temperature. Do not refrigerate — cold thickens the carrier oil and makes drawing/injecting harder. Keep out of reach of children. For research and educational purposes only.

Reviews

There are no reviews yet.

Be the first to review “Boldenone Undecylenate 250 mg Primus Ray Laboratories”

Your email address will not be published. Required fields are marked *

Boldenone Undecylenate

Physical & Chemical Properties for Research Purposes
Chemical structure of Boldenone Undecylenate (C30H44O3) for laboratory analysis
2D structural representation · PubChem CID 197042 ↗
Chemical Identity
# CAS Registry Number 13103-34-9
Σ IUPAC Name [(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl] undec-10-enoate
F Molecular Formula C30H44O3
M Molecular Weight 452.67 g/mol
SMILES C=CCCCCCCCCC(=O)O[C@@H]1CC[C@@H]2[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@H]3CC[C@]12C
InChIKey WSVLPPMCNTCMFS-UHFFFAOYSA-N
Melting Point Oil (liquid at RT) °C
Solubility Insoluble in water; soluble in oils
Biological Half-life 14 days (IM)
PubChem CID 197042 ↗
Pharmacological Profile
Anabolic Rating 100
Androgenic Rating 50
Aromatization Low
Hepatotoxicity None
Detection Time 5 months

Clinical Notes

Dehydrotestosterone — testosterone analogue with an added 1,2-double bond. AR binding is measurable but lower than parent testosterone; the clinically interesting feature is upregulation of erythropoietin production, producing hematocrit drift steeper than any other injectable AAS. Bloodwork pattern: HCT climbs 6–8 percentage points over a 16-week run without compensatory caloric intake changes. Erythrocytosis is the rate-limiting variable, not androgen dose. Aromatisation is low (~half testosterone rate) but estradiol creep occurs on long cycles — AI requirement is patient-specific rather than protocol-wide. Undecylenate ester: 14-day half-life and predictable weekly dosing. Appetite stimulation is direct (hypothalamic NPY pathway) and begins within 2 weeks of protocol initiation.

Known trade names: Equipoise, Boldebal, Boldane

Data sourced from published pharmacological literature and authoritative chemical databases (PubChem, DrugBank, ChEBI). Provided for identification and research reference only.